2026-08-29T16:26:22Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/112092024-09-27T08:45:25Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Fuertes, Teresa author Ramiro, Almudena R author de Yebenes, Virginia G author 2020-10 Non-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-experienced B cells. Thus GCs, the sites of antibody affinity maturation triggered during immune responses, also provide an environment that facilitates B cell oncogenic transformation. miRNAs provide attractive and mechanistically different strategies to treat these malignancies based on their potential for simultaneous modulation of multiple targets. Here, we discuss the scientific rationale for miRNA-based therapeutics in B cell neoplasias and review recent advances that may help establish a basis for novel candidate miRNA-based therapies for B cell-NHL (B-NHL). Trends Immunol. 2020; 41(10):932-947 10.1016/j.it.2020.08.006 1471-4906 Trends in immunology 32888820 http://hdl.handle.net/20.500.12105/11209 miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma.